Reply To: Scripts

Forums Herbalist Scripts Scripts Reply To: Scripts

#2070
AvatarEK
Keymaster

Europe Losing Access to Natural Supplements
 
15 April 2010)– From April 2011, European legislation (EC Directive 2004/24/EC) which has already been passed in 2004 will come into force which will effectively mean that ALL Herbal medicines will disappear from the shelves in our High Streets or internet shops within the EU. Freedom of choice in medicine is being taken away. You will only have access to treatments which are Pharmaceutical Drugs based in order to treat your own and your families ailments. No Chinese herbs, No Ayurvedic (Indian) herbs, No Western herbs, NO MEDICINAL HERBS WHATSOEVER. Chinese medicine practitioners will lose access to the majority of the herbs and medicines on which they rely. Consumers will NOT be able to buy any Chinese herbal products within the EU.–This legislation has been heavily influenced by the pharmaceutical industry, who want to protect their profit and will stand to gain by this legislation. There is not any evidence to prove that herbal medicine present a significant risk to the public under previous and present legislation, when policed properly.—“In the case of something like Chinese medicine, the safety issue is a red herring because hundreds of millions of people safely use Chinese medicine already and incredible amounts of research, safety data, usage data, and AER data is available in Asian countries if the EU officials cared to look into it. A blanket ban on products that have been safely used by billions of people for centuries seems to fly in the face of the modern vision of a harmonious, globally integrated society. “—“Getting a classical herbal medicine from a non-European traditional medicinal culture through the EU registration scheme is akin to putting a square peg into a round hole. The regulatory regime ignores and thus has not been adapted to the specific traditions. Such adaptation is required urgently if the directive is not to discriminate against non-European cultures and consequently violate human rights.”–Despite the petitions and demonstrations from herbal practitioners and consumers, as in April 2010, the UK government is showing clear intention to enforce this ban. Although there is still around 11 months away, some of our suppliers have already taken precautions to stop importing stocks in order to accommodate for this change in law and therefore, we are also reducing the stock level and stop stocking low demand products. We are expecting the shortage of supply on certain herbal products in coming months, as the UK based suppliers are calculating the risk of importing and stocking herbal products as the deadline of ban is looming. We advise our customers to consider stocking up on any medications which you are particularly reliant on, as there is a great chance that they will no longer be available in the UK from next year. Please raise the issue to your local MP and sign the petition here <http://www.gopetition.com/petitions/support-herbal-medicine.html&gt; .
 
Herbal drug crackdown: Millions face having to buy remedies on black market as Europe tightens the rules
Patients could lose access to safe herbal medicines under EU rules, it was claimed yesterday. –Instead they could end up buying potentially dangerous supplies from the black market, say herbalists. –Sales of all herbal remedies, except for a small number of products for ‘mild’ illness, will be banned to the public under the new law to come in in 2011. —–At least six million Britons have consulted a herbal practitioner in the past two years, says research—Almost 2,500 UK qualified herbalists and Chinese medicine practitioners will also lose the right to supply a wide range of herbal medicines, because they are not signed up to a statutory regulation scheme. —Unlike healthcare professionals, there is no regulation of herbalists. –The Government has launched a consultation on whether to bring in statutory regulation – which herbalists support. However, many fear the consultation process is too complicated, which could affect the chances of its success. –At least six million Britons have consulted a herbal practitioner in the past two years, according to research. –Leading medical herbalist Dr Ann Walker said: ‘At present patients have access to top quality herbal products that are manufactured only for professional use, but we won’t be allowed to supply them. –‘Traditional remedies from China and India will only be available through the internet or backstreet suppliers, which could pose a serious health risk to the public.’ –Dr Michael Dixon, of the Prince’s Foundation for Integrated Health, said: ‘We fear if the Government refuses statutory regulation, we will see a black market in herbal products, with unlicensed, potentially dangerous remedies[U1].’ Some of these ‘backstreet’ medicines have been found to contain toxic heavy metals. Dr Dixon said statutory regulation was ‘essential’ but the public consultation closes on November 2. The Department of Health said there was no timeline for further action on a regulation scheme. —-And will this affect just the UK? Apparently not; it will be all of the EU. And the same effort is apparently also underway to essentially do the same in the US — i.e., to rip away from the people of this planet the right and the ability to access and to use nutritional &herbal & other such traditionally effective and time-proven means of supporting and strengthening their own immune-systems and their own health. There is even, now, a legislative push in the US Congress to approve a piece of legislation that, if it passes into law, will greatly increase the control — and the power — and the industry-share — of “Big Agriculture”, at the expense of the small farmer and even, reportedly, say critics, at the expense of the average American, such that he or she will not be legally permitted to even grow a few edibles in the backyard garden. Should this happen, say critics, the consequence will also be that the availability of unadulterated, natural, foods will plummet.
***************************************************************************************************
Lycopene-rich tomato paste helps skin from within
Daily consumption of a lycopene-rich tomato paste reduced reddening of the skin after exposure to UV light, says a new study that supports the skin health potential of lycopene. –The tomato paste, giving a daily lycopene dose of 16 milligrams, was also found to reduce damage to mitochondrial DNA, a measure identified as a reliable marker of UV-ray exposure, according to findings published in British Journal of Dermatology. –“This study supports previous epidemiological, animal and human data reporting protective effects of lycopene and indicates that this agent also protects against UVR-induced tissue damage,” wrote researchers from the University of Manchester and Salford Royal NHS Foundation Trust, and Newcastle University. —“Nutritional photoprotection with tomato products is a promising area for research, and further investigative and clinical studies are required to explore these novel findings,” they added. —As an antioxidant, lycopene has been shown to have heart, blood pressure, prostate, osteoporosis, skin and other benefits in both natural and synthetic form and it has been commonly used in food supplements and nutricosmetic applications. -Study details –Twenty healthy women with an average age of 33 and skin types defined as phototype I/II were recruited to participate in the study. The women were randomly assigned to receive either 55 grams of tomato paste in olive oil, or just olive oil every day for 12 weeks. –Of the 17 women who completed the study, skin samples taken from the buttocks before and after 12 weeks of intervention showed that, while there were no changes in the control group, the dose of UV needed to cause reddening increased from 26.4 mJ/cm2 at the start to 36.6 mJ/cm2 after lycopene supplementation, a result which shows the improved resistance of the skin to reddening. —Furthermore, lycopene supplementation was associated with a reduction in the UVA-induction of the matrix metalloprotease enzyme MMP-1, which plays a key role in degradation of the extracellular matrix during premature skin aging. “We anticipate that a range of commonly consumed foods containing highly processed tomato, could have similar effects if ingested in equivalent amounts, but this requires confirmation in further studies. Our data identifies lycopene-rich tomato paste to have properties appropriate for its potential development in systemic photoprotection,” stated the researchers. –Source: British Journal of Dermatology Published online ahead of print, doi: 10.1111/j.1365-2133.2010.10057.x “Tomato paste rich in lycopene protects against cutaneous photodamage in humans in vivo” Authors: M. Rizwan, I. Rodriguez-Blanco, A. Harbottle, M.A. Birch-Machin, R.E.B. Watson and L.E. Rhodes
 
****************************************************************************************************
Recipe for Tomato Paste—either buy a jar of tomato paste ( usually found in the grocery store in a middle eastern market and sometimes an Italian market—and mix with an olive oil and add the spice paprika and safflower and tumeric and black pepper mix well in olive oil and heat in pan til warm and let stay warm for 5 minutes –constantly stirring the mix as not to burn this—when done allow to cool –you can spoon this in –you can add it a side dish and use like a ketchup with out the sugar or HFCS—mix it in a tomato soup—add it to eggs
This will increase not only the lycopene content but other antioxidants as well—and you get the benefit of the anti cancer properties from these herbs—and you produce an anti aging remedy as well
******************************************************************************************************
“Fingers crossed” for article 13.5 acai antioxidants dossier
German fruit extract supplier TropExtract GMBH has submitted an article 13.5 proprietary and emerging science dossier linking Amazonian superfruit extract acai and antioxidant activity to the European Union health claims process. — Sonja Hoffelner, TropExtract’s master of science nutrition said the company was being realistic about its prospects of success, especially given a limited number of trials in the dossier, and EFSA’s position that antioxidant activity is not necessarily beneficial in the body. –“There are some human intervention trials in our dossier, but only with disappointing results,” [U2]she said. “But there is evidence that an increased dietary intake of antioxidants from fruits are associated with reduced risks of a range of disease, including for example cancer. These results may not prove causality but they do indicate that we should not turn our backs on these compounds.” –She said the company was in dialogue with EFSA about the application. –“According to EFSA’s opinion that there is no evidence provided to establish that having antioxidant activity is a beneficial physiological effect[U3] we will have to cross our fingers,” Hoffelner said. —“But we are speaking with them. Our next step is to specify the substance, which has a beneficial effect on the body. It’s an opportunity to move antioxidants forward.” —TopExtract was planning an in vivo trial that could add to the weight of evidence. –Not sufficient to predict the occurrence of an effect –Earlier this year, EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA issued negative opinions relating to 169 dossiers that included blackcurrant juice; royal jelly; acerola; guava; various grape juices and extracts; honey; olive and olive extracts; hibiscus; chorella algae; green tea; cranberry; lingonberry; sea buckthorn oil; prunes, bananas, resveratrol; pomegranate and pine bark extract. —Other nutrients given the thumbs down included spirulina; triphala; chlorophyll; sulphoraphane glucosinolate; elderberry juice; glutathion; aged garlic; rooibos; ginseng; ginkgo biloba; cherries; echinacea ; bilberry ; curcumin and capsicum[U4]. –In its opinion the NDA stated that: “…no evidence has been provided to establish that having antioxidant activity/content and/or antioxidant properties is a beneficial physiological effect.” –It said it assumed those properties were to, “scavenge free radicals and/or to their reducing capacity.” –On the matter of protecting DNA, proteins and lipids from oxidative damage which were also claimed in the submissions, the NDA noted the absence of human studies using reliable risk factors or biomarkers. —“The evidence provided in the animal and in vitro studies submitted is not sufficient to predict the occurrence of an effect of the food(s)/food constituent(s) on the protection of body cells and molecules such as DNA, proteins and lipids from oxidative damage in vivo in humans,” the NDA said–
 
************************************************************************
GMOs in China
China is currently the sixth largest producer of genetically modified (GM) crops (3.8 million hectares in 2008, behind the United States, Argentina, Brazil, India, and Canada [1]. The Chinese government has granted safety certificates for commercial production of four biotech food and fibre crops, including insect resistant cotton, virus resistant papaya, virus resistant sweet pepper, and delayed ripening tomato. Transgenic plants like poplar and petunia are also approved for production. Among the hundreds of biotech products under development that have been approved for productive testing are insect resistant rice (Bt63), bacterial blight resistant rice (Xa21), high phytase corn, and high oil content canola. Other major crops undergoing field trials include insect resistant corn, high lysine content corn, wheat resistant to pre-harvest germination, and insect resistant soybeans. [U5] The regulatory approval of Chinese crops differs significantly from the regulatory approval processes in North America. In one major area alone, in China GM crops are approved by variety in contrast to regulation in North America where crops are regulated by GM event, as ISIS has insisted [2] (see Biosafety Alert, ISIS report). In North America the GM event, once approved in a variety can be bred into other varieties or land races without further regulatory approval [1]. The Chinese approach on regulating GM food crops is slower and apparently more reliable than regulatory approval in North America. Approval by variety may leave a dangerous loophole if the ‘variety’ actually includes more than one GM event, as it is in the unreliable, unpredictable nature of genetic modification that each event is unique and differs according as to where and in what form the GM insert has landed, and what kind of collateral damage has been done to the host genome (see [3] FAQ on Genetic Engineering, ISIS Tutorial). There is limited private sector research and development in agricultural biotechnology in China [1]. Biotech seed development in China is conducted by public research institutes and universities funded by various parts of the Chinese government, though marketing is often done by affiliated private companies. Foreign investment on research and production of biotech plants, livestock, and aquatic products is prohibited; but it is allowed in conventional seed production. China has approved four biotech crops/products for import as processing materials (soybeans, maize , canola, and cotton). The first batch of safety certificates was granted to imported biotech crops in 2004. The 28 varieties approved for import processing include the following traits: 15 herbicide tolerant, 3 reduced formation of undesirable fatty acids, 5 insect resistant, and 5 insect resistant and herbicide tolerace. Production of seeds for crops that are not genetically modified can be undertaken in partnership with multinational seed producers; but multinational corporation ownership is limited to minority shareholders in joint ventures with Chinese companies.
 
******************************************************************************************************
 
TOP A
[U1]What Fear Mongering–always think in the worse these journalist would have you believe—the better stuff will come thorgh the back streets and the mainstream stuff will all be diluted anyway—soooo who is fearing–MainStream
[U2]The concept of Acai berry having some claims in some effect brings down on it the actually benefit—it is a good berry with antioxidants but the claims on mass reduction if they are legitimate never panned out –so again when you see some of the claims some of the marketing people do with these products you have to be aware that alot of it is hyperboleAcai berry has about the same antioxidant capacity as cherry’s in the USA and the reason for the expense of the berry is due to the fact it is a light covered seed with a papper thin berry so you need alot to get anything out of them
[U3]Again here is a Problem–based on a drug Company running the directives on a nutraceutical as opposed to a pharmaseutical you are going to have this Kind of inaccuracy—the drug comanies for over 50-60 years have lambasted Vitamin C and yet there are 10’s of thousands reesarch reports showing the validity of vitamin C at medium to high dose with any issue–And yet instititions like this run by the FDA will cause this kind of ignorance to thrive and cause people to doubt and be swayed by this type of Misinformation
[U4]Irony is that all of these things do impact benefit to health and longevity— This works agains the EUGENICS PROGRAM being ENACTED– So anything that has Life Extending Properties will be challenged with these Article 13—this is what Scientific America published that the FDA should adopt this type of stupidity—well it is the FDA through the efsa that is regulating Europe so the usa and canada ( not having much of an industry thanks to the gov’t) will follow suit
[U5]China is following the trend of the west and that is Demociding there own people–years ago this would not have happened and today they are following the same dictates of the Monetary system –profit over value–the fact they have released GMO’s at all shows a chink in the Chinese system is there and is being exploited as well—the very fact that they have not allowed foreign research in to assist is telling you that this is all gov’t approved Eugenics–sad to say but in today’s times there is nothing of value with anyone who reaches developmental stages of a 1st world caliber-
 
TOP B
HOME
 
Show of the Week October 15 2010
 
Potential ‘Safe Period’ For Hormone Replacement Use Identified
 
Long-Term Estrogen Therapy Linked To Breast Cancer Risk
 
Estrogen Therapy May Be Associated With Kidney Stones in Postmenopausal Women
 
Estrogen Of Choice
 
RECIPE FOR ESTRIOL CONVERSION —
 
 
************************************************************************
Potential ‘Safe Period’ For Hormone Replacement Use Identified
 
ScienceDaily (Feb. 8, 2009) — A new study makes important new findings on the role of hormone use on the risk of breast cancer, confirming that the use of estrogen plus progesterone increases the risk of both ductal and lobular breast cancer far more than estrogen-only; suggesting a two-year “safe” period for the use of estrogen and progesterone; and finding that the increased risk for ductal cancers observed in long-term past users of hormone replacement therapy drops off substantially two years after hormone use is stopped.–Previous studies have shown that hormone replacement therapy after menopause increases the risk of breast cancer and that use of a regimen that includes both estrogen and progesterone is more detrimental for the breast than the use of estrogen alone. But more data from large prospective studies are needed to fully characterize the impact of exogenous hormones (Exogenousor exogeneous) refers to an action or object coming from outside a system. It is the opposite of endogenous, something generated from within the system ) on breast cancer incidence by type of hormone preparation and histology of the cancer.—To investigate the association in more detail, American Cancer Society epidemiologists led by Eugenia E. Calle, PhD, did a prospective study of 68,369 postmenopausal women who were cancer-free at baseline in 1992. They examined the use of estrogen-only and estrogen and progesterone in current and former users of varying duration, and the subsequent risk of developing invasive ductal and lobular carcinoma of the breast. They also looked at whether the risk for each type of breast cancer and each type of hormone regimen varied by body mass index (BMI), stage of disease at diagnosis, and estrogen receptor (ER) and progesterone receptor (PR) status. For the present study, the follow-up period ended on June 30, 2005.—They confirmed the findings from previous work that estrogen and progesterone increases the risk of both ductal and lobular breast cancer far more estrogen alone. They also found the risk associated with use of estrogen and progesterone increases significantly and substantially within three years of beginning hormone use. The data showed no increased risk for women who used estrogen and progesterone for less than two years, potentially identifying a “safe” period for estrogen and progesterone use.—The study also found no increased risk of breast cancer in women who had stopped using estrogen and progesterone two or more years ago, suggesting a window of two to three years for the risks of estrogen and progesterone both to become apparent after initial use and to diminish after cessation. Few estimates of risk within two to three years of initiation and cessation are available, so these findings need replication in other large studies. The study found the use of estrogen and progesterone was associated with a doubling of risk of lobular cancer after three years of use, and a doubling of risk of ductal cancer with 10 years of use. Estrogen-only use was not associated with increased risk of ductal cancer, even after 20 years of use, but was associated with a 50 percent increase in risk of lobular cancer after 10 years of use.—Story Source: The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by American Cancer Society, via EurekAlert!, a service of AAAS. — Journal Reference: –Eugenia E. Calle et al. —Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer, Published Online: January 20, 2008 DOI: 10.1002/cncr.24101
———————————————————————————————–
Long-Term Estrogen Therapy Linked To Breast Cancer Risk
 
ScienceDaily (May 9, 2006) — Long-term estrogen therapy may be related to a higher risk of breast cancer among postmenopausal women who have had a hysterectomy, according to an article in the May 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals. —Previous studies have linked the use of hormone therapy to breast cancer among postmenopausal women, but have primarily focused on the hormone combination of estrogen plus progestin, according to background information in the article. Recently released results from the Women’s Health Initiative (WHI), a large clinical trial of hormone therapy, found no significant link between estrogen therapy and breast cancer in women who took the hormone for seven years. —Wendy Y. Chen, M.D., M.P.H., Brigham and Women’s Hospital and Dana Farber Cancer Institute, Boston, and colleagues evaluated women who were part of the Nurses’ Health Study, a group of female nurses that have been followed since 1976. In 1980, 11,508 women from the study were postmenopausal and had had a hysterectomy. Every two years the researchers enrolled all the additional women who become postmenopausal and had a hysterectomy, so 28,835 women were included by the end of the study in 2002. Women were asked by questionnaire every two years if they used hormones and whether they had developed breast cancer. For women who developed breast cancer, the researchers obtained permission to review the women’s medical records, which they used to record the hormone receptor information. Tumors were classified as positive or negative for estrogen receptor or progesterone receptor based on how they responded to specific hormonal therapies. —Throughout the study period, 934 invasive breast cancers developed, 226 among women who had never used hormones and 708 among women who were using estrogen at the time. The longer a woman used estrogen, the higher her risk of breast cancer. Those who had been taking estrogen for fewer than 10 years did not appear to have a higher risk than those who had never taken hormones, but those who had been taking estrogen for more than 20 years had a significantly increased risk. The association was strongest for cancers that were estrogen receptor positive and progesterone receptor positive. The results were similar when the researchers evaluated only women who were older than age 60; only women who had begun estrogen therapy after reaching age 50; and only women who were at least age 50 and had undergone a hysterectomy, even if they had not gone through menopause. —“In conclusion, we found that estrogen therapy was associated with an increased risk of breast cancer with longer-term use,” the authors write. “Although current use of estrogen therapy for less than 10 years was not associated with a statistically significant increase in breast cancer risk, the WHI has shown an increased risk of stroke and deep-vein thrombosis in the same time period. Women who take estrogen therapy for prevention or treatment of osteoporosis typically require longer-term treatment and should thus explore other options, given the increased risk of breast cancer with longer-term use.”—(Arch Intern Med. 2006; 166: 1027-1032. Available pre-embargo to media at http://www.jamamedia.org.) –Editor’s Note: This study was supported by a grant from the National Institutes of Health, Bethesda, Md. —Story Source: The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by JAMA and Archives Journals, via EurekAlert!, a service of AAAS —
————————————————————————————————
Estrogen Therapy May Be Associated With Kidney Stones in Postmenopausal Women
 
ScienceDaily (Oct. 12, 2010) — Use of estrogen therapy is associated with an increased risk of developing kidney stones in postmenopausal women, according to a report in the October 11 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.– “Nephrolithiasis [kidney stones] is a common condition that affects 5 percent to 7 percent of postmenopausal women in the United States,” according to background information in the article. “Because the process of kidney stone formation is influenced by a variety of lifestyle and other health-related factors, the true impact of estrogen therapy on the risk of kidney stone formation is difficult to infer from observational studies.” — Using data from the national Women’s Health Initiative study, Naim M. Maalouf, M.D., of the University of Texas Southwestern Medical Center, Dallas, examined data from two trials: 10,739 postmenopausal women with hysterectomy who received either an estrogen-only treatment or matching placebo and 16,608 postmenopausal women without hysterectomy who received either an estrogen plus progestin treatment or matching placebo. Data were collected for an average of 7.1 years in the estrogen-only trial and 5.6 years for the estrogen plus progestin trial. — A total of 335 cases of kidney stones were reported in the active treatment groups, while 284 cases occurred in the placebo groups. The beginning demographic characteristics and risk factors for kidney stones were similar in the two groups, and the authors found that estrogen therapy was associated with a significant increase in risk of kidney stones. The corresponding annualized incidence rate per 10,000 women per year was 39 in the treatment group and 34 in the placebo group. Development of kidney stones was five times more common in women with a history of kidney stones at the beginning of the study, but was not significantly altered by estrogen therapy. In this trial, estrogen therapy increased the risk of development of kidney stones irrespective of age, ethnicity, body mass index, prior hormone therapy use or use of coffee or thiazide diuretics.The authors conclude that their results “indicate that estrogen therapy increases the risk of nephrolithiasis in healthy postmenopausal women. The mechanisms underlying this higher propensity remain to be determined. In view of the sizable prevalence of nephrolithiasis in this segment of the population, these findings need to be considered in the decision-making process regarding postmenopausal estrogen use.”—Story Source:–The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by JAMA and Archives Journals.–Journal Reference: N. M. Maalouf, A. H. Sato, B. J. Welch, B. V. Howard, B. B. Cochrane, K. Sakhaee, J. A. Robbins. Postmenopausal Hormone Use and the Risk of Nephrolithiasis: Results From the Women’s Health Initiative Hormone Therapy Trials. Archives of Internal Medicine, 2010; 170 (18): 1678 DOI: 10.1001/archinternmed.2010.342
 
************************************************************************
Estrogen Of Choice
The body naturally makes three estrogen hormones—estradiol, estrone, and estriol. Since estriol possesses the weakest estrogenic effects of the three, it has been largely overlooked by the medical community.
Many studies show that estriol offers a wealth of potential health benefits—without the dangers that sometimes accompany higher-potency estrogens and synthetic or horse-derived hormones.
Studies suggest that estriol helps relieve menopausal symptoms while benefitting bone and urinary tract health. Estriol may also help improve cardiovascular risk factors and even shows promise in reducing the brain lesions of multiple sclerosis.
The most reliable way to measure estriol levels is through 24-hour urine collection.
Despite abundant evidence to the contrary, the FDA has recently claimed that estriol is not safe. You can act now to help preserve consumers’ access to bioidentical hormones such as estriol by visiting http://www.homecoalition.org.
Fear of cancer prevents many women from restoring youthful hormone levels. When applied through the topical (transdermal) route, estriol is not associated with increased cancer risk. Other methods women can use to prevent hormone-related cancers include consuming abundant vitamin D, cruciferous vegetables, D-glucarate, and lignans, while minimizinghormone induced meat and high-fat BST dairy intake.—Interest in estriol increased as it was discovered that estriol was safer than horse-derived and synthetic hormones in relation to cardiovascular health and potentially cancer risk. Unfortunately, many doctors have not adopted its use, and many bioidentical hormone-replacement regimes use only estradiol, a more potent estrogen with increased associated risks.
 
RECIPE FOR ESTRIOL CONVERSION —IODINE use Lugols iodine or a Iodoral or Nascent form at least once a day or consume foods that are high in Iodine such as sea weed or black walnut hull ( as a tea )Watercress-Irish moss-Iceland moss ( as a tea ice or hot ) as well as use a supplemental form of selenium or again consume foods that have good levels of selenium in them such as brazil nuts—garlic-onions-teas such as hawthorn, Bilberry, Astragalus, Sarsparilla
 
TOP B
 
———————————————————————————————–
 
TOP C
HOME
Show of the Week October 18 2010
 
Prostate Cancer and Preventative Means- Walking Prevents Bone Loss Caused From Prostate Cancer Treatment, Study Shows
Using Nitroglycerin to Treat Prostate Cancer Shows Potential to Halt Disease
Red Wine Compound Shown To Prevent Prostate Cancer– Recipe For Prostate Support
Prostate cancer hormone therapy may raise mortality
Silibinin inhibits established prostate tumor growth
************************************************************************
Walking Prevents Bone Loss Caused From Prostate Cancer Treatment, Study Shows
 
ScienceDaily (Oct. 29, 2007) — Exercise may reduce, and even reverse, bone loss caused by hormone and radiation therapies used in the treatment of localized prostate cancer, thereby decreasing the potential risk of bone fractures and improving quality of life for these men, according to a new study. —“Prostate cancer patients are not routinely advised to exercise. Walking is one tool that prostate cancer patients can use to improve their health and minimize the side effects of cancer and cancer treatments,” said Paula Chiplis, PhD., RN, the lead author of the study and a clinical instructor and senior research assistant at Johns Hopkins Hospital in Baltimore. “Walking has no harmful side effects, if done moderately, but it can dramatically improve life for men suffering from side effects from some prostate cancer treatments.” —Men with localized prostate cancer frequently receive radiation therapy followed by months of hormone therapy to treat their cancer. Radiation is used to kill the cancer cells, while hormone therapy decreases testosterone and estrogen that feed the cancer cells, thereby keeping the tumor from growing. Men undergoing hormone therapy lose between 4 to 13 percent of their bone density on an annual basis, compared to healthy men who lose between .5 to 1 percent per year, beginning in middle age. Men are typically not thought to be at risk for osteoporosis and bone fractures; however, their rate of bone loss is greater than that of post-menopausal women. The study shows that prostate cancer patients undergoing hormone therapy that walked about five times a week for 30 minutes at a moderate pace maintained or gained bone density, while those who didn’t exercise lost more than two percent of their bone density in eight to nine weeks. —The study involved 70 sedentary men with Stage I-III prostate cancer, who were randomly assigned to either participate in the exercise plan or usual care (not exercise) during radiation treatment, with more than half also receiving hormone therapy. Researchers wanted to determine the effects of a nurse-directed, home-based walking program in maintaining physical function and managing cancer- and treatment-related symptoms during radiation and hormone treatment for prostate cancer patients.—This research “Effects of Exercise on Bone Loss & Functional Capacity during Prostate Cancer Treatment,” was presented on October 28, 2007, at the American Society for Therapeutic Radiology and Oncology’s 49th Annual Meeting in Los Angeles.—Story Source: The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by American Society for Therapeutic Radiology and Oncology, via EurekAlert!, a service of AAAS
———————————————————————————————-
 
Using Nitroglycerin to Treat Prostate Cancer Shows Potential to Halt Disease
ScienceDaily (Feb. 11, 2010) — Treatment of prostate cancer using a very low dose of nitroglycerin may slow and even halt the progression of the disease without the severe side effects of current treatments, Queen’s University researchers have discovered.–The findings are the result of the first-ever clinical trial using nitroglycerin to treat prostate cancer. The 24-month, Phase II study targeted 29 men with increasing levels of prostate-specific antigen (PSA) following prostate surgery or radiation. PSA levels are a key predictor of cancer progression.–“We were very excited to see a significant slowing in the progression of the disease as evidenced by the men’s PSA levels, and to see this result in many of the men who completed the study,” says Robert Siemens, the leader of the study and a Professor of Urology at Queen’s University and urologist at Kingston General Hospital.–The researchers are encouraged by the results, particularly because safe and effective treatments for men with rising PSA levels following surgery or radiation are limited. They note that further testing needs to be done to confirm the results of this very small study.–The men were treated with a low-dose, slow-release nitroglycerin skin patch and their PSA levels monitored. Of the 17 patients who completed the study, all but one showed a stabilization or decrease in the rate of cancer progression, as measured by their PSA Doubling Time.—Nitroglycerin has been used at significantly higher doses for more than a century to treat angina. This trial was based on a key finding from pre-clinical research carried out at Queen’s, which showed that decreases in nitric oxide play an important role in tumor progression and that this progression can be stopped by low-dose nitroglycerin.—Prostate cancer is diagnosed in approximately 235,000 men per year in the United States and 20,700 in Canada. Of patients who have undergone radical prostatectomy and/or radiation treatment, it is estimated that 30 to 50 percent will experience a recurrence of cancer. Results of the study, conducted by Queen’s University researchers Robert Siemens, Jeremy Heaton, Michael Adams, Jun Kawakami and Charles Graham, appeared in a recent issue of the journal Urology.–Research into the use of nitroglycerin and similar compounds for the treatment of cancer by Drs. Adams, Graham and Heaton has resulted in the issue of 10 patents worldwide. PARTEQ Innovations, the technology transfer office of Queen’s, has licensed some of this intellectual property to Nometics Inc., a Queen’s spinoff company, which is developing products and therapies based on this and related research.–“This peer-reviewed research is our first clear clinical evidence that low-dose nitric oxide therapy offers prostate cancer patients a new non-invasive treatment option,” says Robert Bender, CEO of Nometics. “It is our intention to start broader clinical trials in 2010 to confirm and expand these results.”-Story Source: Adapted from materials provided by Queen’s University
———————————————————————————————-
 
Red Wine Compound Shown To Prevent Prostate Cancer– Recipe For Prostate Support
ScienceDaily (Sep. 1, 2007) — Researchers at the University of Alabama at Birmingham (UAB) have found that nutrients in red wine may help reduce the risk of developing prostate cancer.The study involved male mice that were fed a plant compound found in red wine called resveratrol, which has shown anti-oxidant and anti-cancer properties. Other sources of resveratrol in the diet include grapes, raspberries, peanuts and blueberries. In the study resveratrol-fed mice showed an 87 percent reduction in their risk of developing prostate tumors that contained the worst kind of cancer-staging diagnosis. The mice that proved to have the highest cancer-protection effect earned it after seven months of consuming resveratrol in a powdered formula mixed with their food. Other mice in the study, those fed resveratrol but still developed a less-serious form of prostate cancer, were 48 percent more likely to have their tumor growth halted or slowed when compared to mice who did not consume the compound, the UAB research team said.This study adds to a growing body of evidence that resveratrol consumption through red wine has powerful chemoprevention properties, in addition to its apparent heart-health benefits, said lead study author Coral Lamartiniere, Ph.D., of UAB’s Department of Pharmacology and Toxicology.An earlier UAB study published May 2006 in the same journal found resveratrol-fed female mice had considerable reduction in their risk of breast cancer. Lamartiniere said his research team has been pleasantly surprised at the chemoprevention power of wine and berry polyphenols like resveratrol in animal models.“ A cancer prevention researcher lives for these days when they can make that kind of finding,” Lamartiniere said. “I drink a glass a day every evening because I’m concerned about prostate cancer. It runs in my family.” Lamartiniere and other researchers say work is already underway to test resveratrol consumption in humans to see what concentrations are needed to convey cancer-prevention benefits.–The amounts used in the UAB mice studies were the equivalent of one person consuming one bottle of red wine per day, which is not advisable. Since drinking alcohol in excessive amounts can have harmful health effects, doctors generally recommend moderate red wine consumption, which is an average of two drinks a day for men and one drink a day for women[U1].–Lamartiniere’s team included researchers from the UAB Department of Pathology and the Comprehensive Cancer Center. Funding support came from the U.S. Department of Defense and the National Cancer Institute.–The findings were published in August through the online edition of the Journal of Carcinogenesis.—Story Source:–Adapted from materials provided by University of Alabama at Birmingham.
Recipe For Prostate Support—One way to increase the potency is to fuse berries or grape extracts into a wine and repeatedly infusing this til there is a saturation and then allowing for some fermentation to take place –this will increase the effect of the antioxidant 0r you can buy the resveratrol and add it to a wine as well and then increasing the impact by using 1 ounce and then add 1 gram to this to get an increase this will suffice at a lower level of consumption—or take the resveratrol
————————————————————————————————
 
Prostate cancer hormone therapy may raise mortality
Tue Sep 23, 6:00 PM ET
In elderly men with early-stage prostate cancer, receiving hormone therapy is associated with an increase in all-cause mortality, according to a study reported Tuesday at the American Society for Therapeutic Radiology and Oncology’s 50th Annual Meeting underway in Boston. “Our study shows that for men over 70 with early-stage prostate cancer, androgen deprivation therapy as a form of treatment may do more harm than good,” said Dr. Amy M. Dosoretz, a radiation oncology resident at the Harvard Radiation Oncology Program in Boston, who led the study. The findings of this study are “potentially practice-changing,” said Dr. Louis Harrison of Beth Israel Medical Center, New York, and moderator of a press briefing where the findings were released. Dosoretz and colleagues reviewed the records of more than 1700 men, at least 70 years of age, with early-stage prostate cancer, who were treated with a short course of hormone therapy — about 3.5 months — before undergoing brachytherapy. Hormone therapy decreases levels of androgen, a hormone that stimulates the growth of prostate cancer cells. Brachytherapy is a procedure in which radiation “seeds” are strategically implanted in the prostate tumor that continuously release small doses of radiation to destroy the cancer cells. Some of the patients received brachytherapy alone. None of the men underwent conventional external-beam radiation therapy. After an average follow-up of 5.0 years, the men who received hormone therapy were 20 percent more likely to die from any cause compared with the men who received brachytherapy alone, Dosoretz reported. The findings were unchanged after the researchers adjusted the data to include the patient’s age and factors known to influence the prognosis of prostate cancer. It’s currently unclear why hormone therapy before radiation seed implantation would increase the risk of death in older men with early-stage prostate cancer, Dosoretz said. However, the presence of other illnesses could raise the risk of treatment-related complications, including cardiovascular complications, she suggested. “Our message is that in older patients it is very important to weigh the risks and benefits of hormone therapy when designing a treatment plan,” Dosoretz told conference participants
 
———————————————————————————————
 
Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice
Singh RP, Raina K, Sharma G, Agarwal R.
Authors’ Affiliations: Department of Pharmaceutical Sciences, School of Pharmacy.
PURPOSE: The chronic nature of prostate cancer growth and progression leading to metastasis provides a large window for intervention. Herein, for the first time, we investigated the effect and associated mechanisms of silibinin phosphatidylcholine (silybin-phytosome) on established prostate tumors in transgenic adenocarcinoma of the mouse prostate (TRAMP) model. EXPERIMENTAL DESIGN: Twenty-week-old TRAMP male mice having palpable prostate tumor were fed with control or 0.5% and 1%, w/w, silybin-phytosome diets for 11 weeks and then sacrificed. RESULTS: Dietary silibinin inhibited the growth of prostate tumors (up to 60%, P < 0.001) and suppressed tumor progression from prostatic intraepithelial neoplasia to differentiated adenocarcinoma and poorly differentiated adenocarcinoma, with a complete absence of poorly differentiated adenocarcinoma at higher doses. It also inhibited the incidence of tumor invasion of seminal vesicle (up to 81%, P < 0.001) with complete absence of distant metastasis. Silibinin moderately inhibited tumor cell proliferation and induced apoptosis, but strongly suppressed tumor microvessel density (up to 60%, P < 0.001), vascular endothelial growth factor, and vascular endothelial growth factor receptor-2 expression. Antibody array analysis of plasma showed a decrease in the circulatory levels of vascular endothelial growth factor and basic fibroblast growth factor. Decreased levels of matrix metalloproteinases (MMP), snail-1, and vimentin, and an increased level of E-cadherin were also observed, indicating the anti-epithelial-mesenchymal transition effect of silibinin in tumors. CONCLUSIONS: Overall, silibinin treatment of TRAMP mice bearing prostate tumor inhibited tumor growth, progression, local invasion, and distant metastasis involving suppression of tumor angiogenesis and epithelial-mesenchymal transition. These findings would have greater relevance for the ongoing phase II clinical trial with silibinin-phytosome in prostate cancer patients.
——————————————————————————————————————————–
 
TOP C
 
 
[U1]That equates to about 6 ounces or half a bottle
 
———————————————————————————————————————————————————————————–
 
TOP D
HOME
 
Show of the Week Oct 22 2010
Peppermint Bug Spray
 
If your child is obese should the government take them away?
 
Genetically Modified Salmon Must Be Labelled
 
Flavonol quantification and stability of phenolics in fermented extracts from fresh Betula pendula leaves
 
FDA warns makers of chelation treatments
 
************************************************************************
Peppermint Bug Spray
 
Combine ingredients in a Mason Jar (2qt, half the ingredients for a 1qt mason jar of course) Use all dried and chopped ingredients. 4tbsp Rosemary 4tbsp Sage
4tbsp Lavender 4tbsp Wormwood 4tbsp Peppermint 2 Quarts Braggs Organic Apple Cider Vinegar (With Mother) Combine all of these ingredients in the jar, shake them up vigorously for at least 2-3 minutes then place in your refrigerator. This must stay in the refrigerator for at last 2 weeks, and you should shake the mixture for at least 1 minute each day. At the end of 2 weeks chop up enough fresh garlic to make 4 tablespoons and add this to the mixture. Store in the refrigerator for another 1-2 weeks, shaking each day as needed. At the end of the 4 weeks strain out any chunks/particles from the mixture to the point it is fine enough to spray in a spray bottle. I grade down my straining from a screen, tea strainer, and finally a coffee filter. In terms of the herbs, I recommend only fresh dried and ground up varieties, it is very cheap, and a single pound will be enough for many many years of
 
************************************************************************
If your child is obese should the government take them away?
It seems England is joining Germany in the ‘war’ against obese children. Parents who fail to help an obese child eat and exercise properly, ignoring all advice and guidance, could be guilty of neglect, child health experts say today.[U1] Doctor Russell Viner and colleagues from the UCL Institute of Child Health in London say that the weight of a child by itself is not a reason for child protection staff to get involved. But in an article on what they accept is a potentially contentious issue, published online today by the British Medical Journal, they suggest that it may be appropriate to consider the child protection register if the parents consistently fail to change the family’s lifestyle and will not engage with outside help. “Parental failure to provide their children with adequate treatment for a chronic illness (asthma, diabetes, epilepsy, etc) is a well accepted reason for a child protection registration for neglect,” they write.—Removing children from their parents may not help obesity. There are few data on the weight of children in public care,” they say. A recent study found that 37% of children in care were overweight or obese – but almost all of them had put on weight after they were put into care.[U2] Yet another example of government pointing the finger at parents. Parents don’t have the millions of dollars to gain political power. The corrupt food production and personal care companies run rampant with toxic ingredients while parents are overwhelmed with which products to chose for their families. I’m sure Big Pharma will be standing at the trough to pump ‘special’ drugs into these imprisoned children. What’s next? ADHD kids will be imprisoned? Obese couples cannot have children? Even worse is data EXISTS for children who have been snatched. Truly disgusting action by wayward governments! How about starting with obese government policy makers!

Life Force Energy